Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.13
(-2.03%)
SEK 0.13
(-2.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 19.8 Million SEK | 1.54% |
| 2022 | 19.5 Million SEK | 9.55% |
| 2021 | 17.8 Million SEK | 11.95% |
| 2020 | 15.9 Million SEK | -1.85% |
| 2019 | 16.2 Million SEK | 62.0% |
| 2018 | 10 Million SEK | 29.63% |
| 2017 | 7.71 Million SEK | -33.53% |
| 2016 | 11.6 Million SEK | 40.42% |
| 2015 | 8.26 Million SEK | 88.34% |
| 2014 | 4.38 Million SEK | -8.73% |
| 2013 | 4.8 Million SEK | 36.6% |
| 2012 | 3.52 Million SEK | 72.25% |
| 2011 | 2.04 Million SEK | 33.12% |
| 2010 | 1.53 Million SEK | 244.87% |
| 2009 | 445.19 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 16 Million SEK | -9.6% |
| 2024 Q3 | 12 Million SEK | -25.0% |
| 2024 Q1 | 17.7 Million SEK | -10.61% |
| 2023 Q4 | 19.8 Million SEK | -9.59% |
| 2023 Q3 | 21.9 Million SEK | -21.51% |
| 2023 Q2 | 27.9 Million SEK | 31.6% |
| 2023 FY | 19.8 Million SEK | 1.54% |
| 2023 Q1 | 21.2 Million SEK | 8.72% |
| 2022 FY | 19.5 Million SEK | 9.55% |
| 2022 Q4 | 19.5 Million SEK | 18.18% |
| 2022 Q3 | 16.5 Million SEK | -10.81% |
| 2022 Q2 | 18.5 Million SEK | 0.54% |
| 2022 Q1 | 18.4 Million SEK | 3.37% |
| 2021 Q1 | 14.9 Million SEK | -6.29% |
| 2021 FY | 17.8 Million SEK | 11.95% |
| 2021 Q3 | 13.8 Million SEK | -8.61% |
| 2021 Q4 | 17.8 Million SEK | 28.99% |
| 2021 Q2 | 15.1 Million SEK | 1.34% |
| 2020 Q3 | 14 Million SEK | 0.72% |
| 2020 Q4 | 15.9 Million SEK | 13.57% |
| 2020 FY | 15.9 Million SEK | -1.85% |
| 2020 Q2 | 13.9 Million SEK | -26.84% |
| 2020 Q1 | 19 Million SEK | 17.28% |
| 2019 Q1 | 17.8 Million SEK | 78.0% |
| 2019 Q2 | 15.8 Million SEK | -11.24% |
| 2019 Q3 | 15.1 Million SEK | -4.43% |
| 2019 Q4 | 16.2 Million SEK | 7.28% |
| 2019 FY | 16.2 Million SEK | 62.0% |
| 2018 Q2 | 13.1 Million SEK | 45.56% |
| 2018 FY | 10 Million SEK | 29.63% |
| 2018 Q4 | 10 Million SEK | 2.04% |
| 2018 Q3 | 9.8 Million SEK | -25.19% |
| 2018 Q1 | 9 Million SEK | 16.66% |
| 2017 Q3 | 6.85 Million SEK | -20.79% |
| 2017 FY | 7.71 Million SEK | -33.53% |
| 2017 Q4 | 7.71 Million SEK | 12.46% |
| 2017 Q2 | 8.65 Million SEK | -52.97% |
| 2017 Q1 | 18.41 Million SEK | 58.66% |
| 2016 Q3 | 5.73 Million SEK | 11.74% |
| 2016 Q4 | 11.6 Million SEK | 102.28% |
| 2016 FY | 11.6 Million SEK | 40.42% |
| 2016 Q1 | 6.12 Million SEK | -25.87% |
| 2016 Q2 | 5.13 Million SEK | -16.19% |
| 2015 Q4 | 8.26 Million SEK | 31.15% |
| 2015 Q1 | 4.93 Million SEK | 12.47% |
| 2015 FY | 8.26 Million SEK | 88.34% |
| 2015 Q3 | 6.3 Million SEK | 15.93% |
| 2015 Q2 | 5.43 Million SEK | 10.14% |
| 2014 Q1 | 4.56 Million SEK | -5.14% |
| 2014 FY | 4.38 Million SEK | -8.73% |
| 2014 Q4 | 4.38 Million SEK | 45.64% |
| 2014 Q3 | 3.01 Million SEK | -51.4% |
| 2014 Q2 | 6.2 Million SEK | 35.93% |
| 2013 Q2 | 8.8 Million SEK | 134.34% |
| 2013 Q1 | 3.75 Million SEK | 6.75% |
| 2013 Q3 | 4.21 Million SEK | -52.15% |
| 2013 Q4 | 4.8 Million SEK | 14.13% |
| 2013 FY | 4.8 Million SEK | 36.6% |
| 2012 Q2 | 2.02 Million SEK | -21.67% |
| 2012 Q1 | 2.58 Million SEK | 26.46% |
| 2012 FY | 3.52 Million SEK | 72.25% |
| 2012 Q4 | 3.52 Million SEK | 52.75% |
| 2012 Q3 | 2.3 Million SEK | 13.84% |
| 2011 Q3 | 2.46 Million SEK | -46.57% |
| 2011 Q2 | 4.6 Million SEK | 294.28% |
| 2011 Q1 | 1.16 Million SEK | -23.88% |
| 2011 FY | 2.04 Million SEK | 33.12% |
| 2011 Q4 | 2.04 Million SEK | -16.98% |
| 2010 FY | 1.53 Million SEK | 244.87% |
| 2010 Q4 | 1.53 Million SEK | 0.0% |
| 2009 FY | 445.19 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -80.033% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.26% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.26% |
| Arcoma AB | 33.3 Million SEK | 40.549% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 93.995% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.393% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 92.926% |
| CellaVision AB (publ) | 212.32 Million SEK | 90.675% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -39.466% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -188.254% |
| C-Rad AB (publ) | 122.4 Million SEK | 83.824% |
| Duearity AB (publ) | 17.53 Million SEK | -12.949% |
| Dignitana AB (publ) | 37.56 Million SEK | 47.294% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.92% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | 3.885% |
| Iconovo AB (publ) | 14.55 Million SEK | -36.046% |
| Integrum AB (publ) | 22.07 Million SEK | 10.297% |
| Luxbright AB (publ) | 7 Million SEK | -182.852% |
| Mentice AB (publ) | 163.55 Million SEK | 87.894% |
| OssDsign AB (publ) | 105.25 Million SEK | 81.189% |
| Paxman AB (publ) | 44.5 Million SEK | 55.515% |
| Promimic AB (publ) | 16.15 Million SEK | -22.555% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 68.151% |
| SciBase Holding AB (publ) | 21.27 Million SEK | 6.946% |
| ScandiDos AB (publ) | 37.18 Million SEK | 46.754% |
| Sectra AB (publ) | 1.64 Billion SEK | 98.794% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 55.063% |
| Senzime AB (publ) | 58.06 Million SEK | 65.9% |
| SpectraCure AB (publ) | 14.97 Million SEK | -32.22% |
| Stille AB | 172.64 Million SEK | 88.531% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.46% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 92.098% |